Occlusions Veineuses Rétiniennes : Prise en charge actualisée

Rogers SL, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–319.e1.

Gallagher M, Younis S, Chavda S, et al. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011;25:981–988.

Hayreh SS, Zimmerman MB. Central retinal vein occlusion: natural history of visual outcome and management. Ophthalmology. 2011;118:119–133.

Hayreh SS, Zimmerman MB. Branch retinal vein occlusion: natural history of visual outcome and management. Ophthalmology. 2014;121.

Schmidt-Erfurth U, Garcia-Arumí J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123–162.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Mariani AF, Regillo CD, et al. Ranibizumab for macular edema following branch retinal vein occlusion: the BRAVO study. Ophthalmology. 2010;117(6):1102–1112.

Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: the CRUISE study. Ophthalmology. 2010;117(6):1124–1133.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion (GENEVA). Ophthalmology. 2010;117:1134–1146.

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema following central retinal vein occlusion: the COPERNICUS study. Ophthalmology. 2012;119:106–112.

Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 24-month results of the GALILEO study. Ophthalmology. 2013;120:xxxx–xxxx.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. A randomized trial of intravitreal aflibercept versus grid laser for macular edema following branch retinal vein occlusion (VIBRANT). Ophthalmology. 2015;122:538–544.

Central Vein Occlusion Study Group. Evaluation of grid-pattern photocoagulation for macular edema in central vein occlusion: CVOS report no. 3. Ophthalmology. 1995;102:1425–1433.

Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: CVOS report no. 4. Ophthalmology. 1995;102:1434–1444.

The SCORE Study Research Group. A randomized trial comparing standard care versus intravitreal triamcinolone for macular edema secondary to branch retinal vein occlusion (SCORE-BRVO). Ophthalmology. 2009;116:222–230.

The SCORE Study Research Group. A randomized trial comparing observation versus intravitreal triamcinolone for macular edema secondary to central retinal vein occlusion (SCORE-CRVO). Ophthalmology. 2009;116:xxx–xxx.

Spaide RF. Peripheral retinal nonperfusion and neovascularization in retinal vein occlusion imaged by widefield fluorescein angiography. Retina. 2011;31:178–182.

Nicholson L, Vazquez-Alfageme C, Patrao NV, et al. Retinal nonperfusion in retinal vein occlusion and its relationship to treatment response and clinical outcomes. Retina. 2020;40:xxxx–xxxx.

Wykoff CC, Ou WC, Khurana RN, Brown DM, Major JC Jr, Wong TP, et al. Long-term outcomes of individualized anti-VEGF therapy for macular edema secondary to retinal vein occlusion. Ophthalmology Retina. 2017;1:314–323.

Ho M, Liu DT, Lam DSC, Jonas JB. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016;36:432–448.

Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, et al. Management of retinal vein occlusion: consensus document. Ophthalmologica. 2011;226:4–28.